Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
5 mg | 約6-8 週間 | ¥ 109,000 |
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
説明 | BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM). |
ターゲット&IC50 | ERG (human):1.52 μM |
In vivo | BKI-1369 reduces the parasite burden and disease severity in the gnotobiotic pig model. BKI-1369 has been well characterized for potency, metabolism, stability, toxicity, pharmacokinetics, and is potent against C. parvum in infected mice and calves. |
分子量 | 417.51 |
分子式 | C23H27N7O |
CAS No. | 1951431-22-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BKI-1369 1951431-22-3 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR BKI 1369 BKI1369 Inhibitor inhibitor inhibit